deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT02117219

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents

Sponsor: MedImmune LLC

Conditions Myelodysplastic Syndrome
Interventions MEDI4736 Evaluate MEDI4736 in MDS VIDAZA tremelimumab
Updated 23 times since 2017 Last updated: May 9, 2019 Started: May 20, 2014 Primary completion: Apr 30, 2019 Completion: Apr 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02117219, this PHASE1 trial focuses on Myelodysplastic Syndrome and remains completed. Sponsored by MedImmune LLC, it has been updated 23 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Sep 2017 · 5 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

23 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

▶ Show 18 earlier versions

  1. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  2. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1

  3. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1

  4. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE1

  5. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  6. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  7. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  8. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

  9. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  10. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  11. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  12. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  13. Dec 2017 — Apr 2018 [monthly]

    Recruiting PHASE1

  14. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

  15. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  16. Apr 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

  17. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE1

  18. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MedImmune LLC
Data source: MedImmune LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Boston, United States , Brighton, United Kingdom , Chicago, United States , Detroit, United States , Dresden, Germany , Greenville, United States , Houston, United States , London, United Kingdom and 10 more locations